FDA sets Feb decision date for Libtayo lung cancer challenge to KeytrudaThe FDA has started a priority review of Regeneron and Sanofi’s checkpoint inhibitor Libtayo in first-line non-small cell Share XFDA sets Feb decision date for Libtayo lung cancer challenge to Keytrudahttps://pharmaphorum.com/news/fda-sets-feb-decision-date-for-libtayos-lung-cancer-challenge-to-keytruda/
NICE changes stance on Keytruda for first-line head and neck cancerAs recently as June, NICE was minded not to back routine NHS of MSD’s Keytruda as a first-line Share XNICE changes stance on Keytruda for first-line head and neck cancerhttps://pharmaphorum.com/news/nice-changes-stance-on-keytruda-for-first-line-head-and-neck-cancer/
New data reinforce Keytruda’s dominance in first-line lung cancerFive-year data with Merck & Co’s Keytruda showing that it doubles survival should help the drug fend off Share XNew data reinforce Keytruda’s dominance in first-line lung cancerhttps://pharmaphorum.com/news/new-data-reinforce-keytrudas-dominance-in-first-line-lung-cancer/
Highlight Therapeutics trials second-line melanoma combo after immunotherapy failsCancer immunotherapy has set new standards in care, with some impressive responses in those patients lucky enough to Share XHighlight Therapeutics trials second-line melanoma combo after immunotherapy failshttps://pharmaphorum.com/news/highlight-therapeutics-trials-second-line-melanoma-combo-after-immunotherapy-fails/
BMS’ Opdivo aces trial in asbestos-linked lung cancerBristol-Myers Squibb’s Opdivo has improved survival in a trial involving patients with mesothelioma, a form of lung cancer, Share XBMS’ Opdivo aces trial in asbestos-linked lung cancerhttps://pharmaphorum.com/news/bms-opdivo-aces-trial-in-asbestos-linked-lung-cancer/
Roche’s Tecentriq flunks triple-negative breast cancer trialRoche’s hopes of extending the use of its PD-L1 inhibitor Tecentriq in triple-negative breast cancer (TNBC) have been Share XRoche’s Tecentriq flunks triple-negative breast cancer trialhttps://pharmaphorum.com/news/roches-tecentriq-flunks-triple-negative-breast-cancer-trial/
Merck & Co’s Keytruda gets new colorectal cancer use after month-long FDA reviewIt’s barely a month since Merck & Co unveiled trial results showing that cancer immunotherapy Keytruda (pembrolizumab) works in colorectal Share XMerck & Co’s Keytruda gets new colorectal cancer use after month-long FDA reviewhttps://pharmaphorum.com/news/merck-cos-keytruda-gets-new-colorectal-cancer-use-after-month-long-fda-review/
Merck & Co’s Keytruda approved for second “tumour agnostic” useMerck & Co’s Keytruda cancer immunotherapy has been approved by the FDA in another “tumour agnostic” use, in Share XMerck & Co’s Keytruda approved for second “tumour agnostic” usehttps://pharmaphorum.com/news/merck-cos-keytruda-approved-for-second-tumour-agnostic-use/
Merck & Co’s Keytruda fails in first line bladder cancerMerck & Co’s bid to become standard care in untreated bladder cancer has run into trouble after its Share XMerck & Co’s Keytruda fails in first line bladder cancerhttps://pharmaphorum.com/news/merck-cos-keytruda-fails-in-first-line-bladder-cancer/
